See more : NIBE Industrier AB (publ) (NDRBF) Income Statement Analysis – Financial Results
Complete financial analysis of Chinook Therapeutics, Inc. (KDNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chinook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ambika Cotton Mills Limited (AMBIKCO.BO) Income Statement Analysis – Financial Results
- Nykredit Invest Balance Offensi (NBIOFKL.CO) Income Statement Analysis – Financial Results
- Uniply Industries Limited (UNIPLY.NS) Income Statement Analysis – Financial Results
- Diwang Industrial Holdings Limited (1950.HK) Income Statement Analysis – Financial Results
- Gatos Silver, Inc. (GATO.TO) Income Statement Analysis – Financial Results
Chinook Therapeutics, Inc. (KDNY)
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.13M | 51.63M | 827.00K | 17.26M | 15.09M | 17.24M | 50.68M | 72.98M |
| Cost of Revenue | 1.72M | 1.69M | 422.00K | 554.00K | 584.00K | 559.00K | 549.00K | 89.00K |
| Gross Profit | 4.41M | 49.94M | 405.00K | 16.70M | 14.50M | 16.68M | 50.13M | 72.89M |
| Gross Profit Ratio | 71.90% | 96.73% | 48.97% | 96.79% | 96.13% | 96.76% | 98.92% | 99.88% |
| Research & Development | 141.21M | 96.99M | 36.05M | 17.01M | 75.84M | 89.38M | 87.72M | 58.65M |
| General & Administrative | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Other Expenses | 1.72M | 1.69M | 422.00K | 299.00K | 3.99M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 115.86M | 123.13M | 122.00M | 86.45M |
| Cost & Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 116.45M | 123.69M | 122.54M | 86.54M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.18M | 0.00 | 15.00K | 33.00K | 0.00 | 0.00 | 2.22M | 494.00K |
| Depreciation & Amortization | 20.89M | 41.87M | 2.25M | 520.00K | 4.95M | 3.99M | 2.55M | 0.00 |
| EBITDA | -164.20M | -57.17M | -53.98M | -19.45M | -101.36M | -106.45M | -71.86M | -13.56M |
| EBITDA Ratio | -2,679.44% | -110.74% | -6,527.45% | -112.68% | -671.84% | -617.51% | -141.79% | -18.59% |
| Operating Income | -185.08M | -99.04M | -56.23M | -19.97M | -101.36M | -106.45M | -71.86M | -13.56M |
| Operating Income Ratio | -3,020.28% | -191.84% | -6,798.91% | -115.69% | -671.84% | -617.51% | -141.79% | -18.59% |
| Total Other Income/Expenses | 4.81M | -170.00K | -27.40M | -64.82M | 5.22M | 3.23M | 2.18M | -25.74M |
| Income Before Tax | -180.27M | -99.21M | -83.63M | -46.52M | -96.14M | -103.23M | -69.68M | -39.31M |
| Income Before Tax Ratio | -2,941.81% | -192.17% | -10,111.85% | -269.55% | -637.24% | -598.80% | -137.50% | -53.86% |
| Income Tax Expense | 4.34M | 2.09M | -2.00M | 332.00K | 783.00K | 11.36M | -21.46M | -99.00K |
| Net Income | -184.62M | -101.30M | -81.62M | -46.85M | -95.36M | -91.86M | -91.15M | -39.21M |
| Net Income Ratio | -3,012.65% | -196.22% | -9,869.65% | -271.47% | -632.05% | -532.88% | -179.85% | -53.73% |
| EPS | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
| Weighted Avg Shares Out (Dil) | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company's Board of Directors...
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at the 60th ERA Congress from June...
Chinook Therapeutics to Present at Upcoming Investor Conferences
SEATTLE , April 27, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the...
Chinook: CHK-336 Trial Pause Creates Buying Opportunity, All Eyes On IgAN Readout
Chinook: CHK-336 Trial Pause Creates Buying Opportunity, All Eyes On IgAN Readout.
Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors
SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of...
Chinook Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following...
Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing in the phase 1 clinical trial of CHK-336...
Chinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
SEATTLE, March 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual...
Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced presentations at the ISN World Congress of Nephrology 2023 from...
Source: https://incomestatements.info
Category: Stock Reports